

22 August 2024

## Osteopore and the University of Chile successfully complete pre-clinical bone implant studies to speed-up regeneration

### Highlights

- Osteopore successfully completes pre-clinical bench and pre-verification bone implant studies in partnership with the Universidad de Chile (University of Chile).
- On 28 September 2022, Osteopore secured US\$360,000 via the Gobierno de Chile (Government of Chile) and the University of Chile to design a novel 3D-printed bone implant.
- The University of Chile is ranked #400 in the *Best Global Universities* globally – and placed #4 in Latin America – by US News.
- Pre-clinical studies centred on developing ground-breaking compounds and materials that integrate with the bone implant and speed up regeneration.
- Osteopore is expected to commence clinical studies in H2 CY 2025.
- The partnership strengthens Osteopore's position in the USD\$68.9 million Latin American (LATAM) medical device and technologies market.<sup>1</sup>

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX: **OSX**; **Osteopore** or **Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce the completion of pre-clinical bench and pre-verification studies in partnership with the University of Chile.

<sup>1</sup> <https://www.marketdataforecast.com/market-reports/latin-america-medical-device-technology-market>



As announced on 28 September 2022, Osteopore secured US\$360,000 in grant capital via the Government of Chile (non-dilutive US\$225,000) and the University of Chile (non-incremental US\$135,000) to develop a potential world-first 3D-printed bone implant capable of accelerating bone regeneration. The University of Chile is ranked 400<sup>th</sup> globally in the *Best Global Universities* – and placed 4<sup>th</sup> in Latin America (LATAM) – by US News.

The project has now completed the bench-testing phase with results indicating cytocompatibility. In addition, through the addition of the innovative compound into Osteopore's bone implants, osteogenic differentiation was increased over the same analysis period as baseline, indicating faster osteogenesis. This was evidenced by a 3-fold increase in cell adhesion of human bone lineage cells and human endothelial cells, and a 2.5-fold increase of bone-mineralizing activity *in vitro*, as compared to the baseline. With these positive results, the project will now progress to pre-clinical studies of bone regeneration in a biological model.

**Commenting on Osteopore's exciting partnership with the University of Chile and its evolution, CEO Dr Yujing Lim, said:**

"It is a great privilege to work with a highly-motivated research and clinical team that would like to make a difference in bone regeneration.

"Albeit at an early stage, we are highly encouraged by the outcomes. We wish the research and clinical team continued success in the next stage of the evaluation", said Dr Lim.

**Commenting on how the Universidad de Chile's partnership supports its commitment to innovation, Deputy Director of Technology Innovation, Gaspar Morgado, said:**

"It is a strategic priority for our university to collaborate with international entities and industry partners on R&D initiatives.

This approach enhances the potential impact of our laboratory-generated knowledge and technologies.

"Our partnership with Osteopore exemplifies our commitment to innovation", said Mr. Morgado.



The research partnership with the University of Chile strengthens Osteopore's position in the LATAM medical device and technologies market, which is expected to reach US\$92.22 million by 2029 from USD\$68.9 million in 2024.<sup>2</sup>

## ENDS

*This announcement dated 22 August 2024 has been authorised for release to the ASX by the Board of Osteopore Limited.*

For more information, please contact:

**Dr Yujing Lim**

Chief Executive Officer

Osteopore Limited

E: [lim\\_yujing@osteopore.com](mailto:lim_yujing@osteopore.com)

**Isaac Stewart**

Media & Investor Relations

Purple

E: [istewart@purple.au](mailto:istewart@purple.au)

### About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

### About Universidad de Chile

The University of Chile was founded on the 19th of November 1842. It is the oldest higher education institution in Chile. Generating, developing, integrating and communicating knowledge in all the areas of knowledge and culture is the mission and basis of the activities of the University.

The University is in the capital city of Santiago de Chile and it is a public university with international quality. All the areas of knowledge are elaborated in their lecture halls and today the university is at the top of the Chilean university system regarding teaching, research, creation and outreach.

---

<sup>2</sup> <https://www.marketdataforecast.com/market-reports/latin-america-medical-device-technology-market>



For personal use only